Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Cancers (Basel) · 2026 · PMC13204926 · PMID 42192867

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

These results establish daratumumab as the first agent to demonstrate an improvement in overall survival with a favorable trend in high-risk SMM, supporting a paradigm shift away from watchful waiting toward early intervention in this patient population.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.